A blinded central radiology review is not the absolute gold standard for assessing patient progression. Expert clinicians argue their holistic assessment, incorporating the patient's clinical status and other biomarkers alongside scans, provides critical context that a disconnected reviewer lacks.

The FDA receives raw and cleaned datasets from sponsors, not just summary reports. Their internal teams conduct independent analyses, which can lead to findings or data presentations in the official drug label that differ from or expand upon what's in the published paper.

Contrary to common belief, centralized radiology review isn't always superior. In blinded trials, local radiologists with specialist knowledge and clinical context can be as, or more, accurate. The PROTEUS trial's investigator-assessed Metastasis-Free Survival (MFS) showed an even stronger treatment effect (HR 0.74) than the blinded central review (HR 0.80).

While studies can measure declines in heart function in young adult cancer survivors, it's hard to prove these changes will translate into clinical events like heart failure. Survivors are often too young for such outcomes to manifest, which may not occur until their 50s or 60s, highlighting a key challenge in survivorship research.

The PROTEUS trial's control arm was ADT plus placebo, not just surgery, specifically to maintain blinding. This design was crucial for ensuring patient retention and compliance with imaging over the seven-year follow-up, preventing high dropout rates that would have compromised the trial's data integrity.

To generate reliable findings from real-world data, researchers must avoid data dredging. The best practice is to simulate a 'target trial' by creating a formal protocol with pre-defined inclusion criteria and a statistical plan, mirroring the rigor of a prospective clinical trial. This approach is even guided by the FDA.

The study reported that no patients in the "before 3 PM" group ever received a dose after 3 PM over four cycles. In a busy, real-world cancer center, such perfect adherence is practically impossible due to logistical issues. This flawless data suggests the study might be a retrospective analysis of curated data rather than a truly prospective trial.

The CREST trial's positive primary endpoint, assessed by investigators in an open-label setting, was rendered negative upon review by a blinded independent committee. This highlights the critical risk of confirmation bias and the immense weight regulators place on blinded data to determine a drug's true efficacy, especially when endpoints are subjective.

Beyond informing oncologists, evidence of dexrazoxane's effectiveness provides reassurance to patients and their families. Knowing the risk of long-term heart damage from chemotherapy can be mitigated helps them make more informed, less anxious decisions about accepting necessary but aggressive treatment regimens.